Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bw 825c
2. Bw-825c
3. Bw825c
4. Semprex
1. 87848-99-5
2. Semprex
3. Acrivastin
4. Acrivastinum
5. Acrivastina
6. Bw 825c
7. Bw-825c
8. Bw A825c
9. Chebi:83168
10. (e)-6-((e)-3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic Acid
11. 2-propenoic Acid, 3-(6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl)-, (e,e)-
12. A20f9xai7w
13. 2-propenoic Acid,3-[6-[(1e)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-,(2e)-
14. (e)-3-[6-[(e)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic Acid
15. Ncgc00182053-02
16. Acrivastinum [latin]
17. Acrivastina [spanish]
18. Acrivastine [usan:inn:ban]
19. (2e)-3-{6-[(1e)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic Acid
20. Acrivastine (usan/inn)
21. Unii-a20f9xai7w
22. (e)-6-((e)-3-(1-pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure
23. Acrivastine [mi]
24. Acrivastine [inn]
25. Dsstox_cid_2555
26. Acrivastine [usan]
27. Acrivastine [vandf]
28. Schembl4702
29. Acrivastine [mart.]
30. Chembl1224
31. Dsstox_rid_76625
32. Dsstox_gsid_22555
33. Acrivastine [who-dd]
34. Mls006010115
35. Bidd:gt0209
36. Bw270c
37. Dtxsid6022555
38. Acrivastine, >=98% (hplc)
39. Acrivastine [orange Book]
40. Hms3886e20
41. Bcp06189
42. Hy-b1510
43. Zinc3776633
44. Tox21_113015
45. Ac-912
46. Bdbm50487466
47. Benadryl Allgy Relief Plus Decongest
48. Mfcd00869830
49. S5718
50. Akos005067182
51. Semprex-d Component Acrivastine
52. Cs-6454
53. Db09488
54. Ncgc00182053-03
55. (2e)-3-{6-[(1e)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic Acid
56. Acrivastine Component Of Semprex-d
57. As-14623
58. Smr004701250
59. Cas-87848-99-5
60. D02760
61. D70156
62. 848a995
63. A916142
64. Q342745
65. Sr-01000942220
66. Q-200590
67. Sr-01000942220-1
68. (e)-3-{6-[3-pyrrolidino-1-(4-tolyl)prop-1e-enyl]-2-pyridyl}acrylic Acid
69. 6-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic Acid
70. (e)-3-(6-((e)-3-(pyrrolidin-1-yl)-1-(p-tolyl)prop-1-en-1-yl)pyridin-2-yl)acrylic Acid
71. 3-(6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl)-
72. 2-propenoic Acid, 3-[6-[(1e)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]-2-pyridinyl]-, (2e)-
Molecular Weight | 348.4 g/mol |
---|---|
Molecular Formula | C22H24N2O2 |
XLogP3 | 1.6 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 6 |
Exact Mass | 348.183778013 g/mol |
Monoisotopic Mass | 348.183778013 g/mol |
Topological Polar Surface Area | 53.4 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 514 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.
FDA Label
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AX - Other antihistamines for systemic use
R06AX18 - Acrivastine
Absorption
Acrivastine was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 0.23 hour.
Route of Elimination
A mass balance study in 7 healthy volunteers showed that acrivastine is primarily eliminated by the kidneys. Over a 72-hour collection period, about 84% of the administered total radioactivity was recovered in urine and about 13% in feces, for a combined recovery of about 97%.
Volume of Distribution
0.46 0.05 L/kg
Clearance
2.9 0.7 mL/min/kg
The mean terminal half-life for acrivastine was 1.9 0.3 hours following single oral doses and increased to 3.5 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 1.4 hours.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
ABOUT THIS PAGE
A Acrivastine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acrivastine, including repackagers and relabelers. The FDA regulates Acrivastine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acrivastine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Acrivastine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Acrivastine supplier is an individual or a company that provides Acrivastine active pharmaceutical ingredient (API) or Acrivastine finished formulations upon request. The Acrivastine suppliers may include Acrivastine API manufacturers, exporters, distributors and traders.
click here to find a list of Acrivastine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Acrivastine DMF (Drug Master File) is a document detailing the whole manufacturing process of Acrivastine active pharmaceutical ingredient (API) in detail. Different forms of Acrivastine DMFs exist exist since differing nations have different regulations, such as Acrivastine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Acrivastine DMF submitted to regulatory agencies in the US is known as a USDMF. Acrivastine USDMF includes data on Acrivastine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Acrivastine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Acrivastine suppliers with USDMF on PharmaCompass.
A Acrivastine written confirmation (Acrivastine WC) is an official document issued by a regulatory agency to a Acrivastine manufacturer, verifying that the manufacturing facility of a Acrivastine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Acrivastine APIs or Acrivastine finished pharmaceutical products to another nation, regulatory agencies frequently require a Acrivastine WC (written confirmation) as part of the regulatory process.
click here to find a list of Acrivastine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Acrivastine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Acrivastine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Acrivastine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Acrivastine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Acrivastine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Acrivastine suppliers with NDC on PharmaCompass.
Acrivastine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Acrivastine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Acrivastine GMP manufacturer or Acrivastine GMP API supplier for your needs.
A Acrivastine CoA (Certificate of Analysis) is a formal document that attests to Acrivastine's compliance with Acrivastine specifications and serves as a tool for batch-level quality control.
Acrivastine CoA mostly includes findings from lab analyses of a specific batch. For each Acrivastine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Acrivastine may be tested according to a variety of international standards, such as European Pharmacopoeia (Acrivastine EP), Acrivastine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acrivastine USP).
LOOKING FOR A SUPPLIER?